ImmuPharma plc (LON:IMM – Get Free Report) fell 11.7% during mid-day trading on Thursday . The stock traded as low as GBX 3.75 ($0.05) and last traded at GBX 3.80 ($0.05). 14,936,349 shares changed hands during trading, a decline of 25% from the average session volume of 19,799,125 shares. The stock had previously closed at GBX 4.31 ($0.05).
ImmuPharma Trading Up 2.6 %
The firm has a market cap of £16.58 million, a price-to-earnings ratio of -6.74 and a beta of 1.53. The company’s 50-day moving average is GBX 2.77 and its 200-day moving average is GBX 2.04.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Which Wall Street Analysts are the Most Accurate?
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Where Do I Find 52-Week Highs and Lows?
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
